IcoCell
Cell line development platform for SMEs to reduce the length and cost of biologic drug development
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0IcoCell project word cloud
Explore the words cloud of the IcoCell project. It provides you a very rough idea of what is the project "IcoCell" about.
Project "IcoCell" data sheet
The following table provides information about the project.
| Coordinator |
ICOSAGEN CELL FACTORY OU
Organization address contact info |
| Coordinator Country | Estonia [EE] |
| Project website | https://icosagen.com/icocell |
| Total cost | 1˙614˙000 € |
| EC max contribution | 1˙129˙800 € (70%) |
| Programme |
1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-2-2015 |
| Funding Scheme | SME-2 |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-05-01 to 2018-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ICOSAGEN CELL FACTORY OU | EE (KAMBJA VALD) | coordinator | 1˙129˙800.00 |
Map
Project objective
Biologic drugs ($160 billion market) provide better long-term health outcomes with fewer side effects than many traditional drugs. However, due to high development and production costs, these drugs are 20x more expensive, on average, limiting the access to these therapies and burdening healthcare systems. To a great extent, this is because traditionally flexible and creative biotech SMEs currently lack rational tools for mammalian cell line development (most of the biologic drugs are produced in mammalian cell lines), meaning that large investment in terms of capital and time is required to make a production cell line.
ICF, an established player in the biotechnology industry, develops a technology for more efficient development of mammalian cell lines for high-yield protein production. It reduces the need for robotic systems and high-throughput screening facilities (€900 000 -> €200 000), the time (6-12 months -> 3) and cost (€100 000 -> €50 000) of cell line development. These advantages stem from specific landing platforms, predefined integration sites, recombination-dependent insertion and amplification of expression units. The technology will enable biotech SMEs to develop the process of production of new biologic drugs at lower costs and faster, eventually enabling biologic drugs to penetrate more cost-sensitive indications and target groups.
IcoCell project is aimed at optimizing the landing platform, generating cell lines compatible with process of development of industrial cell factories, generating regulatory documentation, preparing standard operating procedures, demonstrating the production of different types of proteins and implementing initial exploitation activities.
Cell line development market is expected to grow at CAGR of 12.8% (2014-2022) and the market for cell line development to produce therapeutic proteins exceeds €900M. Commercialization of IcoCell technology will mean breakthrough for ICF, increasing revenues by an estimated €26M in 2021
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ICOCELL" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ICOCELL" are provided by the European Opendata Portal: CORDIS opendata.